Mark A. Goldsmith, a member of the board at Revolution Medicines, Inc. (NASDAQ: RVMD), completed multiple sales of the companys common stock on March 2, 2026, that together amounted to $3,644,353. The transactions were carried out in tranches with execution prices spanning from $98.1708 to $102.1994 and in a separate set from $98.29 to $102.08.
Breaking down the total, $3,036,576 of the sales were transacted at prices between $98.1708 and $102.1994. The remaining $607,777 came from additional transactions priced between $98.29 and $102.08. At the time of reporting, Revolution Medicines shares were trading at $100.42, a level that represents a 165% gain over the past 12 months. InvestingPro analysis cited in company commentary indicates the shares may be trading above their Fair Value estimate.
Alongside the sales, Goldsmith carried out option exercises. On March 2 he exercised options to acquire 30,000 shares at an exercise price of $4.09 per share, amounting to $122,700. On March 1 Goldsmith reported an acquisition of 57,100 shares of common stock valued at $0. Also on March 1, he secured 128,600 shares through stock options with an exercise price of $102.02.
After these transactions, Goldsmiths reported holdings were detailed as follows: 289,569 shares held directly; 64,424 shares held indirectly through the Rebecca Goldsmith Revocable Trust; 65,224 shares held indirectly through the Jonathan Goldsmith Revocable Trust; and 594,060 shares held indirectly through the Mark A. Goldsmith and Anne E. Midler 2002 Revocable Living Trust.
Investors seeking further analysis are pointed to the Pro Research Report on InvestingPro, which covers Revolution Medicines and more than 1,400 other U.S. equities.
Revolution Medicines also released fourth-quarter 2025 results that showed an 87% year-over-year increase in net loss. Management attributed the deterioration in the quarter to research and development expenses that exceeded estimates by $21.1 million, and selling, general, and administrative costs that were $15.4 million above forecasts. Despite the wider loss, the company reported $2.03 billion in cash and investments at quarter end, a balance noted as being supported in part by a strategic partnership with Royalty Pharma.
Market participants and analysts have responded with varied assessments. UBS initiated coverage with a Buy rating, pointing to the promise of the companys RAS inhibitors in multiple solid tumor indications. Piper Sandler expressed confidence in the drug development program and raised its price target to $120 while keeping an Overweight rating. Needham trimmed its price target to $145 owing to higher costs but retained a Buy rating. Wells Fargo raised its price target to $144, pointing to clinical progress, particularly for daraxon in pancreatic ductal adenocarcinoma.
The companys recent insider transactions, quarterly expense overruns, cash position, and mixed analyst reactions together paint a picture of active management of equity stakes and divergent market expectations for Revolution Medicines as it progresses through clinical development and commercial planning.